{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:09:50Z","timestamp":1771409390099,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":167,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long-acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family peptide receptor 1 (RXFP1), showed trends of increased stroke volume and estimated glomerular filtration rate (eGFR) in HF patients (NCT04630067). The hypothesis is that AZD3427 may enhance GFR by expanding the functional renal cortex volume and improving renal perfusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Re-PERFUSE study (NCT06611423) is a Phase 1b, randomised, double-blind, placebo-controlled trial aimed at evaluating the effects of AZD3427 on renal perfusion in patients with HF and reduced ejection fraction (HFrEF) with reduced eGFR. Patients with HF, EF \u2264 40% and an eGFR of 30 to 90 mL\/min\/1.73 m2, assessed by the CKD-EPI 2021, will receive a single dose of subcutaneous AZD3427 (n = 6) or placebo (n = 6). Intravenous dopamine will serve as a positive control for increased renal blood flow. Positron emission tomography (PET) imaging with [15O]-labelled water will be used to measure renal cortex blood flow pre- and post-treatment, allowing differentiation between global and focal renal blood flow changes and providing insights into potential nephron recruitment and increased filtration membrane area. Safety and tolerability will be assessed through monitoring of adverse events, clinical laboratory tests and vital signs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study, alongside other ongoing AZD3427 studies, aims to evaluate the dual effects of AZD3427 in improving both cardiac and renal function. These insights could guide the development of future therapeutic strategies for managing HF and renal impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15412","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T03:26:52Z","timestamp":1757042812000},"page":"4495-4502","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-PERFUSE: Phase 1b Study of AZD3427, a Novel Relaxin Receptor Agonist, on Renal Perfusion in HFrEF Patients"],"prefix":"10.1093","volume":"12","author":[{"given":"Marcin","family":"Ufnal","sequence":"first","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena P.","family":"Quintana-Hayashi","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Connolly","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pettersen","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Csel\u00e9nyi","sequence":"additional","affiliation":[{"name":"PET Science Centre at Karolinska Institutet, PMB, R&D Oncology, AstraZeneca , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Healthcare Services , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelija","family":"Jucaite","sequence":"additional","affiliation":[{"name":"PET Science Centre at Karolinska Institutet, PMB, R&D Oncology, AstraZeneca , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Healthcare Services , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Schou","sequence":"additional","affiliation":[{"name":"PET Science Centre at Karolinska Institutet, PMB, R&D Oncology, AstraZeneca , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Healthcare Services , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Varrone","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Healthcare Services , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Chan","sequence":"additional","affiliation":[{"name":"Biometrics, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Mississauga, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2026021804165867900_ehf215412-bib-0001","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm12124121","article-title":"Cardiorenal syndrome: challenges in everyday clinical practice and key points towards a better management","volume":"12","author":"Georgopoulou","year":"2023","journal-title":"J Clin Med"},{"key":"2026021804165867900_ehf215412-bib-0002","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10090352","article-title":"Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome","volume":"10","author":"Lekawanvijit","year":"2018","journal-title":"Toxins (Basel)"},{"key":"2026021804165867900_ehf215412-bib-0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114058","article-title":"Diuretic resistance in patients with kidney disease: challenges and opportunities","volume":"157","author":"Guo","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026021804165867900_ehf215412-bib-0004","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bph.13529","article-title":"Anti-fibrotic actions of relaxin","volume":"174","author":"Samuel","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026021804165867900_ehf215412-bib-0005","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026021804165867900_ehf215412-bib-0006","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"2026021804165867900_ehf215412-bib-0007","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804165867900_ehf215412-bib-0008","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2026021804165867900_ehf215412-bib-0009","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021804165867900_ehf215412-bib-0010","first-page":"470","article-title":"Mapping of local renal blood flow with PET and H(2)(15)O","volume":"43","author":"Alpert","year":"2002","journal-title":"J Nucl Med"},{"key":"2026021804165867900_ehf215412-bib-0011","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/ehf2.14933","article-title":"Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease","volume":"11","author":"Zahir Anjum","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021804165867900_ehf215412-bib-0012","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000324","article-title":"Prevalence and prognostic impact of kidney disease on heart failure patients","volume":"3","author":"Lofman","year":"2016","journal-title":"Open Heart"},{"key":"2026021804165867900_ehf215412-bib-0013","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"2026021804165867900_ehf215412-bib-0014","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034067","article-title":"Novel relaxin receptor RXFP1 agonist AZD3427 in the treatment of heart failure: a phase 1a\/b, first-in-human, randomized, single-blind, placebo-controlled study","volume":"13","author":"Connolly","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026021804165867900_ehf215412-bib-0015","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/ndt\/gfae112","article-title":"Volenrelaxin (LY3540378) increases renal plasma flow: a randomized phase 1 trial","volume":"40","author":"Tham","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804165867900_ehf215412-bib-0016","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1152\/ajpregu.00148.2017","article-title":"Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure","volume":"314","author":"Deng","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026021804165867900_ehf215412-bib-0017","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jcph.433","article-title":"Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations","volume":"55","author":"Dahlke","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2026021804165867900_ehf215412-bib-0018","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/eurheartj\/eht371","article-title":"Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF","volume":"34","author":"Metra","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021804165867900_ehf215412-bib-0019","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026021804165867900_ehf215412-bib-0020","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/CIRCHEARTFAILURE.114.001536","article-title":"Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study","volume":"7","author":"Voors","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026021804165867900_ehf215412-bib-0021","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00392-016-0979-8","article-title":"Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF","volume":"105","author":"Liu","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2026021804165867900_ehf215412-bib-0022","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1172\/JCI104996","article-title":"Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow","volume":"43","author":"McDonald","year":"1964","journal-title":"J Clin Invest"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4495\/66968443\/eschf_12_6_4495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4495\/66968443\/eschf_12_6_4495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:17:02Z","timestamp":1771406222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4495\/8488174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15412","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}